Chronic Hepatitis B
Conditions
Brief summary
The primary objectives of this study are to evaluate the safety and tolerability of study treatment(s) (selgantolimod-containing combination therapies) and to evaluate the efficacy of study treatment(s) as measured by the proportion of participants who achieve functional cure, defined as hepatitis B surface antigen (HBsAg) loss and hepatitis B virus (HBV)deoxyribonucleic acid (DNA) \< lower limit of quantitation (LLOQ) at Follow-up (FU) Week 24 in participants with chronic hepatitis B (CHB).
Interventions
DRUGTenofovir Alafenamide
Administered as film-coated oral tablets
DRUGVIR-2218
Administered as a sub-cutaneous (SC) injection
DRUGNivolumab
Administered intravenously
DRUGSelgantolimod
Administered as film-coated oral tablets
Sponsors
Vir Biotechnology, Inc.
Gilead Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Willing and able to provide informed consent * Chronic HBV infection for at least 6 months * Willing to follow protocol-specified contraception requirement Key
Exclusion criteria
* Have extensive fibrosis or cirrhosis in the liver * Have or had liver cancer (hepatocellular carcinoma) * Have an autoimmune disease * Have chronic liver disease other than HBV * Females who are breastfeeding, pregnant, or who wish to become pregnant during the study Note: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Achieved Functional Cure | At Follow-up Week 24 (Cohort 1 and Cohort 2A: At Week 60; Cohort 2B: At Week 48) | Functional cure was defined as hepatitis B surface antigen (HBsAg) loss and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) less than the lower limit of quantitation (LLOQ) at follow-up Week 24. LLOQ for HBV DNA CAP/CTM 2.0 is 20 IU/mL. LLOQ for HBV DNA Cobas 6800 is 10 IU/mL. The HBsAg loss was defined as HBsAg changing from positive at baseline to negative at any postbaseline visit. Percentages were rounded off. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | Up to Follow-up Week 48 (Cohort 1 and Cohort 2A: At Week 84; Cohort 2B: At Week 72) | HBsAg loss was defined as HBsAg changing from positive at baseline to negative at any postbaseline visit. HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative/missing at baseline to positive at a postbaseline visit. Percentages were rounded-off. |
| Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | Up to Follow-up Week 48 (Cohort 1 and Cohort 2A: At Week 84; Cohort 2B: At Week 72) | HBeAg loss is defined as HBeAg changing from positive at baseline to negative at any postbaseline visit. HBeAg seroconversion was defined as HBeAb test changing from negative or missing at baseline to positive at a postbaseline visit. Percentages were rounded-off. |
| Percentage of Participants Who Remain Off NUC Treatment During Follow-Up | Cohort 1 and Cohort 2A: From Week 36 up to Week 84 and for Cohort 2B: From Week 24 up to Week 72 | NUC treatments included for analysis: adefovir dipivoxil, entecavir, telbivudine, tenofovir, tenofovir alafenamide, tenofovir alafenamide fumarate, tenofovir disoproxil fumarate, and lamivudine. Percentages were rounded-off. |
| Percentage of Participants Experiencing Hepatitis B Virus (HBV) Virologic Breakthrough During Study Treatments | Up to 36 Weeks | Virologic breakthrough was defined as confirmed HBV DNA ≥ LLOQ after 2 consecutive HBV DNA \< LLOQ in participants who are complying with NUC therapy or confirmed HBV DNA ≥ 1 log10 IU/mL increase from nadir during study treatments. LLOQ for HBV DNA CAP/CTM 2.0 is 20 IU/mL. LLOQ for HBV DNA Cobas 6800 is 10 IU/mL. Percentages were rounded-off. |
Countries
Australia, Denmark, Hong Kong, New Zealand, Singapore, South Korea, Thailand, United Kingdom
Participant flow
Recruitment details
Participants were enrolled at study sites in Australia, Denmark, Hong Kong, New Zealand, Singapore, South Korea, Thailand, and the United Kingdom.
Pre-assignment details
165 participants were screened.
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab NUC -suppressed participants with CHB received TAF 25 mg orally QD for 36 weeks and VIR-2218 200 mg SC Q4W for 24 weeks. From Week 12 onwards, participants also received SLGN 3 mg orally QW for 24 weeks and nivolumab 0.3 mg/kg IV Q4W for up to 24 weeks (only up to protocol amendment 2, nivolumab was no longer administered post implementation of protocol amendment 2). Participants who were on TAF treatment continued TAF treatment over the duration of study follow-up. Participants were followed up for 48 weeks post treatment. | 42 |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab Viremic participants with CHB received VIR-2218, 200 mg SC Q4W for 24 weeks. From Week 12 onwards, participants also received SLGN 3 mg orally QW for 24 weeks and nivolumab 0.3 mg/kg IV Q4W for up to 24 weeks (only up to protocol amendment 2, nivolumab was no longer administered post implementation of protocol amendment 2). Participants who met the criteria to initiate NUC treatment received TAF 25, mg orally, QD during the study. Participants were followed up for 48 weeks post treatment. | 40 |
| Cohort 2 Group B: SLGN + Nivolumab Viremic participants with CHB received SLGN 3 mg orally QW for 24 weeks and nivolumab 0.3 mg/kg IV Q4W for up to 24 weeks.
Viremic participants who met the criteria to initiate NUC treatment received TAF 25 mg orally QD during the study. Participants were followed up for 48 weeks post treatment.
All treatments were administered up to protocol amendment 2 and after the implementation of protocol amendment 2, the treatments were discontinued for Cohort 2 Group B based on Sponsor decision. | 20 |
| Total | 102 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Enrolled but never treated | 0 | 0 | 1 |
| Overall Study | Investigator's discretion | 0 | 1 | 0 |
| Overall Study | Withdrew consent | 1 | 3 | 0 |
Baseline characteristics
| Characteristic | Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Cohort 2 Group B: SLGN + Nivolumab | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 42 Participants | 40 Participants | 20 Participants | 102 Participants |
| Age, Continuous | 48 years STANDARD_DEVIATION 8.1 | 42 years STANDARD_DEVIATION 7.9 | 44 years STANDARD_DEVIATION 7.9 | 45 years STANDARD_DEVIATION 8.5 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 40 Participants | 39 Participants | 20 Participants | 99 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Asian | 41 Participants | 37 Participants | 18 Participants | 96 Participants |
| Race/Ethnicity, Customized Race Black or African American | 1 Participants | 2 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized Race Other or More Than One Race | 0 Participants | 1 Participants | 2 Participants | 3 Participants |
| Region of Enrollment Australia | 2 participants | 2 participants | 1 participants | 5 participants |
| Region of Enrollment Denmark | 1 participants | 1 participants | 0 participants | 2 participants |
| Region of Enrollment Hong Kong | 19 participants | 10 participants | 7 participants | 36 participants |
| Region of Enrollment New Zealand | 2 participants | 1 participants | 2 participants | 5 participants |
| Region of Enrollment Singapore | 2 participants | 8 participants | 4 participants | 14 participants |
| Region of Enrollment South Korea | 6 participants | 2 participants | 1 participants | 9 participants |
| Region of Enrollment Thailand | 8 participants | 13 participants | 5 participants | 26 participants |
| Region of Enrollment United Kingdom | 2 participants | 3 participants | 0 participants | 5 participants |
| Sex: Female, Male Female | 16 Participants | 25 Participants | 10 Participants | 51 Participants |
| Sex: Female, Male Male | 26 Participants | 15 Participants | 10 Participants | 51 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 42 | 0 / 40 | 0 / 21 |
| other Total, other adverse events | 34 / 42 | 37 / 40 | 19 / 20 |
| serious Total, serious adverse events | 2 / 42 | 5 / 40 | 3 / 20 |
Outcome results
Primary
Percentage of Participants Who Achieved Functional Cure
Functional cure was defined as hepatitis B surface antigen (HBsAg) loss and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) less than the lower limit of quantitation (LLOQ) at follow-up Week 24. LLOQ for HBV DNA CAP/CTM 2.0 is 20 IU/mL. LLOQ for HBV DNA Cobas 6800 is 10 IU/mL. The HBsAg loss was defined as HBsAg changing from positive at baseline to negative at any postbaseline visit. Percentages were rounded off.
Time frame: At Follow-up Week 24 (Cohort 1 and Cohort 2A: At Week 60; Cohort 2B: At Week 48)
Population: The Full Analysis Set included all enrolled participants in Cohort 1, or all randomized participants in Cohort 2 who received at least 1 dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants Who Achieved Functional Cure | 2.4 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants Who Achieved Functional Cure | 2.5 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants Who Achieved Functional Cure | 0.0 percentage of participants |
95% CI: [-2.3, 7.3]
Secondary
Percentage of Participants Experiencing Hepatitis B Virus (HBV) Virologic Breakthrough During Study Treatments
Virologic breakthrough was defined as confirmed HBV DNA ≥ LLOQ after 2 consecutive HBV DNA \< LLOQ in participants who are complying with NUC therapy or confirmed HBV DNA ≥ 1 log10 IU/mL increase from nadir during study treatments. LLOQ for HBV DNA CAP/CTM 2.0 is 20 IU/mL. LLOQ for HBV DNA Cobas 6800 is 10 IU/mL. Percentages were rounded-off.
Time frame: Up to 36 Weeks
Population: Participants in the Full Analysis Set were analyzed.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants Experiencing Hepatitis B Virus (HBV) Virologic Breakthrough During Study Treatments | 7.1 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants Experiencing Hepatitis B Virus (HBV) Virologic Breakthrough During Study Treatments | 35.0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants Experiencing Hepatitis B Virus (HBV) Virologic Breakthrough During Study Treatments | 20.0 percentage of participants |
Secondary
Percentage of Participants Who Remain Off NUC Treatment During Follow-Up
NUC treatments included for analysis: adefovir dipivoxil, entecavir, telbivudine, tenofovir, tenofovir alafenamide, tenofovir alafenamide fumarate, tenofovir disoproxil fumarate, and lamivudine. Percentages were rounded-off.
Time frame: Cohort 1 and Cohort 2A: From Week 36 up to Week 84 and for Cohort 2B: From Week 24 up to Week 72
Population: The Follow-Up Analysis Set included all participants who have at least 1 follow-up visit, after completing or premature discontinued from the study drugs.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants Who Remain Off NUC Treatment During Follow-Up | 16.7 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants Who Remain Off NUC Treatment During Follow-Up | 55.6 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants Who Remain Off NUC Treatment During Follow-Up | 75.0 percentage of participants |
Secondary
Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion
HBsAg loss was defined as HBsAg changing from positive at baseline to negative at any postbaseline visit. HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative/missing at baseline to positive at a postbaseline visit. Percentages were rounded-off.
Time frame: Up to Follow-up Week 48 (Cohort 1 and Cohort 2A: At Week 84; Cohort 2B: At Week 72)
Population: Participants in the Full Analysis Set were analyzed. In Cohort 2 Group B, participants received study treatment for up to 24 weeks. Thereafter, participants were followed up for 48 weeks. Therefore, data for Weeks 28, 32, and 36 are not reported for this cohort in this outcome measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 14 | 2.4 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 8 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 4 | 4.8 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 4 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 4 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 8 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 12 | 2.4 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 12 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 14 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 16 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 16 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 20 | 4.8 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 20 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 24 | 4.8 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 24 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 28 | 4.8 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 28 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 32 | 4.8 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 32 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 36 | 4.8 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 36 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Follow-up (FU) Week 2 | 4.8 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 2 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 4 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 8 | 4.8 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 8 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 12 | 7.1 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 12 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 24 | 4.8 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 24 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 36 | 7.1 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 36 | 2.4 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 48 | 7.1 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 48 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 16 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 24 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 12 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 28 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 48 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 24 | 2.5 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 32 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 36 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 48 | 2.5 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 24 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Follow-up (FU) Week 2 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 4 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 28 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 32 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 36 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 2 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 36 | 2.5 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 4 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 4 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 4 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 8 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 8 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 12 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 12 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 8 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 14 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 14 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 8 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 16 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 36 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 20 | 2.5 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 12 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 20 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 24 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 16 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 8 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 4 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 20 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 8 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 14 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 20 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 12 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 48 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 24 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 36 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 12 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 24 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 48 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 8 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 12 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 8 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 12 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 4 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 24 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 4 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 14 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: Week 4 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: FU Week 36 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Follow-up (FU) Week 2 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 24 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss and Seroconversion: FU Week 2 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With HBsAg Loss With and Without Anti-HBsAg Seroconversion | HBsAg Loss: Week 16 | 0 percentage of participants |
Secondary
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline
HBeAg loss is defined as HBeAg changing from positive at baseline to negative at any postbaseline visit. HBeAg seroconversion was defined as HBeAb test changing from negative or missing at baseline to positive at a postbaseline visit. Percentages were rounded-off.
Time frame: Up to Follow-up Week 48 (Cohort 1 and Cohort 2A: At Week 84; Cohort 2B: At Week 72)
Population: Participants in the Full Analysis Set with HBeAg positive at Baseline were analyzed. In Cohort 2 Group B, participants received study treatment for up to 24 weeks. Thereafter, participants were followed up for 48 weeks. Therefore, data for Weeks 28, 32, and 36 are not reported for this cohort in this outcome measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 36 | 11.1 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 14 | 11.1 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 12 | 16.7 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 12 | 5.6 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 4 | 5.6 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 24 | 5.6 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 14 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 24 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 36 | 11.1 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 8 | 11.1 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 36 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 16 | 11.1 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 48 | 16.7 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 48 | 5.6 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 16 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 20 | 11.1 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 8 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 20 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 24 | 16.7 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 8 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 24 | 5.6 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 12 | 11.1 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 28 | 16.7 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 28 | 5.6 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 32 | 11.1 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 32 | 5.6 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 36 | 5.6 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 2 | 5.6 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 2 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 4 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 4 | 16.7 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 12 | 0 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 4 | 5.6 percentage of participants |
| Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 8 | 11.1 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 8 | 6.3 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 4 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 8 | 6.3 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 20 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 8 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 12 | 6.3 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 14 | 6.3 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 36 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 12 | 6.3 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 24 | 6.3 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 4 | 6.3 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 24 | 12.5 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 36 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 24 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 24 | 12.5 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 14 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 12 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 36 | 12.5 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 2 | 6.3 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 28 | 6.3 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 36 | 6.3 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 12 | 6.3 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 28 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 48 | 12.5 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 16 | 6.3 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 4 | 6.3 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 48 | 6.3 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 20 | 6.3 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 8 | 6.3 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 32 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 16 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 4 | 0 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 2 | 6.3 percentage of participants |
| Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 32 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 48 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 4 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 4 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 8 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 8 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 12 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 12 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 14 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 14 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 16 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 16 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 20 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 20 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: Week 24 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: Week 24 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 2 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 2 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 4 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 4 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 8 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 8 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 12 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 12 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 24 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 24 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 36 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss and Seroconversion: FU Week 36 | 0 percentage of participants |
| Cohort 2 Group B: SLGN + Nivolumab | Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss With and Without Anti-HBeAg Seroconversion in Participants With CHB Who Are HBeAg-Positive at Baseline | HBeAg Loss: FU Week 48 | 0 percentage of participants |